Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218638 | 0.84 | AADAT (0.41) | NPC1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL16784448 | 0.77 | KMT2A (0.57) | NPC1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL30922327 | 0.77 | NPC1 (0.45) | NPC1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL11931354 | 0.77 | MET (0.44) | NPC1MEN1KMT2ARAB9AAADAT | |
| SCHEMBL25334568 | 0.73 | NPC1 (0.54) | NPC1MEN1KMT2ARAB9APTGS2 | |
| SCHEMBL26694723 | 0.72 | CRHR1 (0.43) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29180296 | 0.72 | MAPT (0.56) | NPC1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL14329228 | 0.72 | SMN1; SMN2 (0.56) | NPC1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL26694601 | 0.72 | PIK3CA (0.41) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL17385333 | 0.71 | MEN1 (0.45) | NPC1MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7605155-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-7601724-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-10-13 | — | — | US | disclosed |
| US-7563798-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2008045267-A2 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045266-A2 | PYRAZOLOPYRIMIDIWES AS CYCLIN DEPENDENT KINASE INHIBITOR | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045268-A2 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070072880-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072882-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072882-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | NPC1 3746/4885MEN1 3191/4885KMT2A 1051/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | NPC1 2445/4885MEN1 2806/4885KMT2A 1517/4885 |
| US-20070072880-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | NPC1 3746/4885MEN1 3191/4885KMT2A 1051/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | NPC1 2445/4885MEN1 2806/4885KMT2A 1517/4885 |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | NPC1 3746/4885MEN1 3191/4885KMT2A 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.